Novo Nordisk A/S (NVO) delivered a first-quarter report that regarded spectacular at first look. Internet gross sales reached DKK 96,823 million, up 24% in Danish kroner and 32% at fixed alternate charges, whereas reported working revenue rose to DKK 59,618 million, up 54% in kroner and 65% at CER. Administration additionally raised its 2026 outlook, citing stronger expectations for GLP-1 product gross sales.
However the headline progress charges don’t inform the total story. As soon as the corporate’s non-recurring 340B provision reversal is stripped out, the quarter appears to be like materially softer. Adjusted internet gross sales have been DKK 70,063 million, down 10% in kroner and 4% at CER, whereas adjusted working revenue was DKK 32,858 million, down 15% in kroner and 6% at CER. For traders, that makes this a way more nuanced quarter than the preliminary high-line beat suggests.
What the Headline Q1 Numbers Say
The headline figures assist the concept Novo Nordisk stays one of the crucial vital progress tales in massive-cap healthcare. Reported gross sales and reported working revenue each elevated sharply, and administration was assured sufficient to raise its outlook for the 12 months.
That confidence will not be onerous to know. Novo continues to learn from huge demand for GLP-1 therapies, and the corporate’s product pipeline additionally added supporting milestones through the quarter, together with FDA approval for Wegovy HD and approval of Awiqli, its as soon as-weekly basal insulin for kind 2 diabetes.
If traders look solely on the reported figures and the upper steering, the quarter reads like one other clear affirmation that Novo nonetheless controls one of many strongest franchises in world prescribed drugs.
Why Wegovy Tablet Is Driving the Story
The true working spotlight was the early launch trajectory of Wegovy tablet within the U.S. Novo mentioned the remedy generated Q1 2026 gross sales of DKK 2,256 million after its January launch. Complete prescriptions since launch have now surpassed 2 million, and weekly prescriptions exceeded 200,000 by the week ending April 17.
These are placing numbers as a result of they counsel Novo could also be opening a new progress lane slightly than merely extending its injectable weight problems franchise. Administration described the product because the strongest-ever GLP-1 quantity launch within the U.S., and the quarter’s raised steering was explicitly tied to stronger expectations for GLP-1 gross sales.
Weight problems care stays the middle of the story. Adjusted weight problems-care gross sales elevated 22% at CER, reinforcing the view that Novo nonetheless has significant demand momentum whilst competitors within the class continues to accentuate.
What the Adjusted Figures Reveal About Pricing Stress
The complication is that the underlying enterprise was not as sturdy because the headline progress charges indicate. The reported numbers have been boosted by a non-recurring provision reversal associated to the 340B Drug Pricing Program within the U.S. Excluding that profit, each adjusted gross sales and adjusted working revenue declined.
That softer underlying image seems to be pushed largely by pricing strain within the U.S. Novo mentioned adjusted U.S. gross sales fell 11% at CER due to decrease realized costs, regardless that quantity progress throughout the Wegovy portfolio remained sturdy. Worldwide Operations have been more healthy, with gross sales up 6% at CER, but the U.S. pricing dynamic is the important thing challenge traders can’t ignore.
That is the stress within the inventory now. Novo can nonetheless report highly effective headline progress and launch momentum, but the economics beneath these numbers have gotten extra contested. That doesn’t break the bull case, but it does make the subsequent few quarters extra vital in figuring out how sturdy GLP-1 profitability actually is.
What the Raised Outlook Means for the GLP-1 Growth Narrative
The raised outlook continues to be significant as a result of it reveals administration believes the demand backdrop is powerful sufficient to offset no less than a part of the pricing strain. Novo now expects adjusted gross sales progress for 2026, excluding the 340B reversal, of unfavourable 4% to unfavourable 12% at CER and adjusted working-revenue progress in the identical vary.
That steering will not be as sturdy because the headline quarter may initially counsel, but it does point out administration sees sufficient assist from the Wegovy franchise to enhance expectations. In impact, Novo is telling traders that quantity progress and product momentum stay highly effective, even when pricing and blend are making the trail much less simple.
For the market, the takeaway is evident: the quarter was ok to assist a larger outlook, but not clear sufficient to take away doubts about underlying pricing energy within the U.S. weight problems enterprise.
Key Indicators for Traders
- Reported Q1 progress was sturdy, but the adjusted figures present the quarter depended closely on a one-time 340B-associated profit.
- Wegovy tablet gross sales of DKK 2,256 million and greater than 2 million prescriptions since launch level to a doubtlessly main new progress driver.
- Adjusted U.S. gross sales fell 11% at CER, making realized pricing an important working threat to look at.
- Worldwide gross sales progress of 6% at CER supplies some diversification, but it doesn’t absolutely offset strain within the U.S. base.
- The upper 2026 outlook helps the lengthy-time period GLP-1 thesis, but traders will seemingly demand cleaner underlying progress in coming quarters.
Source link
#Novo #Nordisk #NVO #Raises #View #Adjusted #Growth #Tells #Complicated #Story #Alphastreet
